Pancreatic Ductal Adenocarcinoma
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Pancreatic Ductal Adenocarcinoma

What is the definition of Pancreatic Ductal Adenocarcinoma?
Pancreatic ductal adenocarcinoma is an aggressive cancer that occurs in the linings of the tubes of the pancreas that carry enzymes to the intestines that assist with digestion.
What are the symptoms of Pancreatic Ductal Adenocarcinoma?
Early pancreatic ductal adenocarcinoma may not have any symptoms. Symptoms of pancreatic ductal adenocarcinoma may include yellowing of the skin and whites of the eyes, fatigue, dark urine, light-colored or greasy stools, itchy skin, abdominal or back pain, weight loss, nausea and vomiting, gallbladder or liver enlargement, blood clots, and diabetes.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Pancreatic Ductal Adenocarcinoma?
Treatment for pancreatic ductal adenocarcinoma includes surgery, radiation therapy, and chemotherapy.
Who are the top Pancreatic Ductal Adenocarcinoma Local Doctors?
Elite in Pancreatic Ductal Adenocarcinoma
General Surgery
Elite in Pancreatic Ductal Adenocarcinoma
General Surgery
Referral may be required

UT Southwestern Medical Center

1801 Inwood Rd, 
Dallas, TX 
Languages Spoken:
English
Offers Telehealth

Jason Fleming is a General Surgeon practicing medicine in Dallas, Texas. Dr. Fleming is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Elite in Pancreatic Ductal Adenocarcinoma
Elite in Pancreatic Ductal Adenocarcinoma
Referral may be required
Vancouver, BC, CA 

Daniel Renouf practices practicing medicine in Vancouver, Canada. Mr. Renouf is rated as an Elite expert by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Familial Pancreatic Cancer, Colorectal Cancer, and Pancreatectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Pancreatic Ductal Adenocarcinoma
Elite in Pancreatic Ductal Adenocarcinoma
Referral may be required

Samuel Oschin Cancer Center

127 S San Vicente Blvd # 7, 
Los Angeles, CA 
Languages Spoken:
English
Offers Telehealth

Andrew Hendifar is a Hematologist practicing medicine in Los Angeles, California. Dr. Hendifar is rated as an Elite provider by MediFind in the treatment of Pancreatic Ductal Adenocarcinoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Ampullary Cancer, Gastroesophageal Junction Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

What are the latest Pancreatic Ductal Adenocarcinoma Clinical Trials?
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

Summary: This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Summary: This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).